Mechanisms and Refinements of PSCA Directed Antibody Therapy
Annual rept. 17 Dec 2001-17 Dec 2002
CALIFORNIA UNIV LOS ANGELES
Pagination or Media Count:
PSCA is a cell surface antigen expressed by a majority of prostate, bladder and pancreatic cancers. An antibody against PSCA has preclinical activity against prostate cancer xenografts. The mechanism of this activity is not known. The goals of this project include 1 determining whether anti-tumor activity is Fc-region dependent or independent or both and 2 testing combination therapies to identify potential synergies or antagonisms that may be relevant to the clinic. We have also proposed to develop humanized antibodies for potential translation to the clinic.
- Anatomy and Physiology
- Medicine and Medical Research